10.1038/s41586-020-2639-4 - Phase I/II study of COVID-19 RNA vacc...

This document has been corrected

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

10.1038/s41586-020-2639-4

Published Online: 2020-08-12

Journal: Nature•Publisher: Springer Science and Business Media LLC

Authors: Alejandra Gurtman•Ann R. Falsey•Camila Fontes-Garfias•David Cooper•Edward E. Walsh•Judith Absalon•Kathleen Neuzil•Kathrin U. Jansen•Kena A. Swanson•Kenneth Koury•Kirsten E. Lyke•Kristin R. Tompkins•Mark J. Mulligan•Nicholas Kitchin•Pei-Yong Shi•Philip R. Dormitzer•Ping Li•Robert Frenck•Ruth Bailey•Stephen Lockhart•Uğur Şahin•Vanessa Raabe•Warren Kalina•William C. Gruber•Özlem Türeci

This document has been corrected

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

10.1038/s41586-020-2639-4

Published Online: 2020-08-12

Journal: Nature

NOW

2021-01-19•Correction

Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

10.1038/s41586-020-03098-3

* information provided by CrossRef

2021-01-19•Correction

10.1038/s41586-020-03098-3

* information provided by CrossRef

2020-08-12•Published

2021-01-19•Correction

Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

10.1038/s41586-020-03098-3

* information provided by CrossRef

This document has been corrected

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

10.1038/s41586-020-2639-4

Published Online: 2020-08-12

Journal: Nature•Publisher: Springer Science and Business Media LLC